

Implementation of an Outpatient Parenteral Antimicrobial Therapy (OPAT) Collaborative for Patients with *Staphylococcus aureus* or Gram-Negative Bacilli Bacteremia Requiring Home Infusion: The PANTHIR Program

Jennifer K. Ross, PharmD, BCIDP^{1,2}; Kimberly D. Boeser, PharmD, MPH, BCIDP^{1,2}; Malia Hain, PharmD Candidate⁴; Kristi Killelea, PharmD, BCPS²; Dana Simonson, PharmD, BCPS²; Alison Galdys, MD³

¹M Health Fairview University of Minnesota Medical Center; ²Fairview Pharmacy Services; ³University of Minnesota; ⁴University of Minnesota College of Pharmacy; Minneapolis, MN



BACKGROUND

- Outpatient parenteral antimicrobial therapy (OPAT) has been shown to be safe, efficacious, and cost-effective^{1,2,6}
- Methicillin-susceptible or methicillin-resistant *Staphylococcus aureus* (MSSA, MRSA) or Gram-negative bacilli (GNB) bacteremia often requires extended parenteral antibiotic(s) and is associated with significant morbidity and mortality⁴
- Home infusion pharmacists can retrieve OPAT discharge orders from the electronic health record (EHR) to ensure completion of OPAT care plans, including drug therapy monitoring and follow-up

METHODS

- Retrospective review of patients (≥ 18 years) at the University of Minnesota Medical Center with MRSA, MSSA, or GNB bacteremia using home infusion services within M Health Fairview over a 26-month period (4/2016-6/2018)
- Gap analysis and creation of the Parenteral Antimicrobial therapy Transitions to Home Infusion Review (PANTHIR) program as an interdisciplinary collaborative with ID providers, ID pharmacists, clinical information specialist, and home infusion pharmacists
- Core PANTHIR program core elements:
 - Inpatient identification
 - ID pharmacist review
 - OPAT care plan coordination
 - OPAT outcome analysis

Hospital readmission rates, emergency department (ED) visits, and adverse drug events (ADEs) are frequent among patients with MRSA, MSSA, or Gram-negative bacilli bacteremia requiring OPAT via home infusion.



30-day unplanned hospitalizations (n=69)		30-day ED visits (n=69)	
Total (%)	OPAT-related (%)	Total (%)	OPAT-related (%)
16 (23)	4 (5.8)	21 (30)	8 (12)

Total (%) ADEs (n=69)	Mild (%) ADEs	Moderate (%) ADEs	Severe (%) ADEs
18 (26)	8 (12)	8 (12)	2 (3)



CONCLUSIONS

- The transition from inpatient to outpatient care is a vulnerable period for successful delivery of OPAT due to potential for communication errors that can translate to imprecise care plans
- Both unplanned hospitalizations within 30 days of discharge and ADEs are higher than published outcomes among OPAT patients with heterogenous infections^{3,5}
- Our cohort also represents a shorter duration of therapy (22 days) and use of less nephrotoxic agents with only 1 patient receiving vancomycin and no receipt of aminoglycosides
- Next, we plan to compare post-implementation outcomes to determine PANTHIR program impact, broaden retrospective review to target high risk groups, and expand OPAT collaborative reach to all patients discharging on parenteral antimicrobial therapy

1. Chung EK et al. Am J Health Syst Pharm. 2016;73(1):e24-33.
2. Gilchrist M and Seaton RA. J Antimicrob Chemother. 2015;70(4):965-70.
3. Keller SC et al. Clin Infect Dis. 2018;66:11-19.
4. Laupland KB. Clin Infect Dis. 2013;19(6):492-500.
5. Means L et al. Pharmacotherapy. 2016;36:934-939.
6. Norris AH et al. Clin Infect Dis. 2019;68:e1-e35.